SEARCH:      Monitor Keywords |  Custom RSS

Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof September class, title,number 09/11

20110237774 - Method for introducing dota: The invention provides a method for introducing 1,4,7,10-tetraazacyclododecane-N,N′,N″,N′″-tetraacetic acid (DOTA) into a compound such as a peptide. The method comprises a first step for preparing a mixed liquid of DOTA having no protecting group and dimethylsulfoxide, and a second step for contacting the mixed liquid with the compound carried on... Agent: Riken

20110237775 - Methods for characterizing glycoproteins and generating antibodies for same: The invention provides methods for preparing a peptide useful in generating an antibody specific for the glycosylated form of a glycopolypeptide wherein the glycosylated portion is isolated and a peptide corresponding to amino acids adjacent to a glycosylated N-linked glycosylation site is prepared.... Agent:

20110237776 - Aromatic compounds with sulfur containing ligands: e

20110237777 - Fusion protein containing a single-stranded dna binding protein and methods for expression and purification of the same: The present invention provides an expression vector comprising a promoter and a polynucleotide sequence encoding a fusion protein. The present invention further provides a method for purification of an interest protein. The present invention also provides a fusion protein comprising a single-stranded DNA binding protein and an interest protein or... Agent:

20110237778 - Process for the extraction of macromolecules from a biomass using thin stillage: e

20110237780 - Anti-inflammatory dab: The present invention provides a recombinant domain antibody (dAb) which binds to human TNF-α, the dAb comprising an immunoglobulin heavy or light chain variable domain, wherein said variable domain comprises at least one complementarity determining region (CDR) having a sequence derived from a New World primate.... Agent: Peptech Limited

20110237779 - Cdr-repaired antibodies: The present application concerns restoring antigen binding during humanization of antibodies through the selection of repaired hypervariable regions rather than through framework changes.... Agent: Genentech, Inc.

20110237781 - Method of preparing alpha-1 proteinase inhibitor: Purification of α-1 proteinase inhibitor (α-1 PI) from solutions comprising α-1 PI is accomplished using hydrophobic interaction chromatography (HIC). In some embodiments, purification of α-1 PI is accomplished by precipitation of contaminating proteins from a starting solution comprising α-1 PI, such as human plasma, followed by anion exchange resin chromatography... Agent: Talecris Biotherapeutics, Inc.

20110237782 - Methods for glyco-engineering plant cells for controlled human o-glycosylation: This invention discloses the development of a novel platform for recombinant production of bioactive glycoproteins and cancer specific vaccines in plants. Plants and plant cell cultures have been humanized with respect to human mucin-type protein O-glycosylation. A panel of plant cell factories for production of recombinant glycoproteins with designed human... Agent:

20110230637 - Modified human thymic stromal lymphopoietin: Modified, furin resistant human TSLP polypeptides and polynucleotides encoding the modified human TSLP polypeptides are provided. Pharmaceutical compositions, B and T cell activation agents, assays and methods of use are also described.... Agent: Immunex Corporation

20110230638 - Methods for detection of cyclosporin a: Methods and reagents are disclosed for determining the presence and/or amount of cyclosporin A in a medium suspected of containing cyclosporin A. In the method a combination is provided in a medium. The combination comprises (i) the sample, (ii) a first member of a signal producing system (sps) associated with... Agent: Siemens Healthcare Diagnostics Inc.

20110230639 - Immunomodulatory peptides: The invention relates to peptides derivatized with a hydrophilic polymer which, in some embodiments, bind to human FcRn and inhibit binding of the Fc portion of an IgG to an FcRn, thereby modulating serum IgG levels. The disclosed compositions and methods may be used in some embodiments, for example, in... Agent: Syntonix Pharmaceuticals Inc.

20110230640 - Methods for characterizing glycoproteins and generating antibodies for same: The invention provides methods for preparing a peptide as an immunogen to generate an antibody specific for the deglycosylated form of a glycopolypeptide by preparing a peptide that includes an N-linked glycosylation site of said glycopolypeptide and identifying a peptide sequence that includes said glycosylated site and preparing said peptide... Agent:

20110230641 - Preparation of alkenes by mild thermolysis of sulfoxides: Embodiments of this disclosure, among others, encompass methods for generating alkenes under mild thermolytic conditions that can provide almost total conversion of a precursor compound to an alkene without isomerization or the need to chromatographically purify the final product By selectively blocking the amino and carboxy groups of the deπvatized... Agent:

20110230642 - Method for increasing recloning efficiency: b

20110230643 - Recombinant flagellin protein and preparation and use thereof: The present invention provides an optimized recombinant flagellin protein and preparation and use thereof. The protein is with a deletion in the hypervariable region, said hypervariable region is the region from 180 to 400 amino acid of the flagellin protein, and the proteins include FliCΔ190-278, FliCΔ220-320 or FliCΔ180-400. The method... Agent:

20110230644 - Microbubbles for affinity separation: The present invention relates to methods, compositions and kits for affinity isolation, affinity purification and affinity assay based on microbubbles coated with an affinity molecule. Particularly, the invention provides protein microbubbles coated with an affinity molecule. In addition, the invention provides glass microbubbles coated with an affinity molecule. Methods of... Agent:

20110230645 - Purification of factor v: The invention provides methods for purifying blood coagulation Factor V from biological fluids.... Agent: Crucell Holland B.v.

20110230646 - Hybrid antibodies: Hybrid antibodies and/or hybrid antibody fragments and methods of making them are provided. In one embodiment the hybrid antibodies and/or hybrid antibody fragments 5 contain heavy and/or light variable regions that contain two or more framework regions derived from at least two antibodies. In another embodiment, at least two of... Agent: Alexion Pharmaceuticals, Inc.

20110230647 - Compositions and methods for modulating lymphocyte activity: The present invention provides a novel lymphocyte inhibitory receptor termed BTLA which is expressed on both T and B cells, and identifies HVEM as interacting with BTLA. Methods and compositions for modulating BTLA-mediated signaling and interfering with the interaction of BTLA and HVEM for therapeutic, diagnostic and research purposes are... Agent: The Washington University

20110230648 - Method of binding bacterial lipopolysaccharides to a solid phase: The subject the present invention is a method of producing affinity beds with bacterial lipopolysaccharide molecules bound to them in a non-covalent and stable fashion. The bed produced according to the present invention may be used in affinity chromatography for the purification of antibodies against lipopolysaccharides. It is particularly useful... Agent:

20110230649 - Compositions and methods for redox modulated proteins: Disclosed embodiments relate to antibodies that recognize redox modulated proteins such as glutathionylated actin. Embodiments relate to a reagent for the immunoassay of glutathionylated actin. Disclosed embodiments also relate to diagnosis of and therapies for the treatment of diseases related to impaired deglutathionylation of peptides. Additionally, disclosed embodiments relate to... Agent: Nitan Biotech LLC

20110230650 - Compositions and methods for solubilizing membrane proteins without the use of detergent: Disclosed are compositions and methods for isolating proteins from lipids. The isolation methods may utilize derivatives of apolipoprotein A1 for isolating membrane proteins from membranes without the use of detergent.... Agent: Northwestern University

20110224404 - Method for development of a peptide building block useful for de novo protein design: The present invention relates to a top-down symmetric deconstruction approach which provides a novel alternative means to successfully identify a useful polypeptide “building block” for subsequent “bottom-up” de novo design of target protein architecture. The present invention also pertains to a novel peptides isolated by top-down symmetric deconstruction which may... Agent: Florida State University Research Foundation

20110224405 - Degradable supports for tide synthesis: According to the present invention, there is provided a process for synthesis of a first compound selected from peptides, oligonucleotides, and peptide nucleic acids, which comprises synthesis of the first compound linked to a soluble support, wherein the soluble support is degraded following the synthesis so that it can be... Agent: Imperial Innovations Limited

20110224406 - Interleukin-9 receptor mutants: This invention relates to the diagnosis, treatment and methods for discovery of new therapeutics for atopic asthma and related disorders based on variants of Asthma Associated Factor 2. One embodiment of the invention is a variant of AAF2 wherein codon 173 is deleted resulting in the loss of glutamine 173... Agent:

20110224407 - Type i interferon antagonists: Disclosed in certain embodiments is a method of preparing a Type 1 interferon antagonist comprising modifying a Type 1 interferon at the site of interaction with the interferon receptor subunit IFNAR-1 such that the binding affinity of the interferon to the IFNAR-1 subunit is reduced as compared to the native... Agent: Yeda Research And Development Co., Ltd.

20110224408 - Treatment and prophylaxis of amyloidosis: Methods useful for effecting prophylaxis or treatment of amyloidosis, including AA Amyloidosis and AL amyloidosis, by administering peptides comprising neoepitopes, such as AA fragments from a C-terminal region of AA, and antibodies specific for neoepitopes of aggregated amyloid proteins, for example, antibodies specific for the C-terminal region of AA fibrils.... Agent: University Of Tennessee Research Foundation

20110224409 - Sialic acid derivatives: An amine or hydrazide derivative of a sialic acid unit, e.g. in a polysaccharide, is reacted with a bifunctional reagent at least one of the functionalities of which is an ester of N-hydroxy succinimide, to form an amide or hydrazide product. The product has a useful functionality, which allows it... Agent:

20110224410 - Buffers for controlling the ph of bone morphogenetic proteins: The present invention provides formulations of cysteine knot proteins, including TGF-β superfamily proteins and bone morphogenic proteins that are pH stabilized. In particular, the present invention relates to the observation that certain buffers enhance the stability of cysteine knot proteins, including TGF-β superfamily proteins and bone morphogenic proteins. In particular,... Agent:

20110224411 - Mutant trna for introducing unnatural amino acid into protein: It is an objective of the present invention to provide tRNA that has CUA or CCCG as an anticodon and is aminoacylated with an unnatural amino acid, such tRNA being capable of efficiently introducing an unnatural amino acid into a protein without competing with a termination factor. Such tRNA is... Agent: Japan Science And Technology Agency

20110218325 - Inhibitor of endogenous human interferon-gamma: Inactivated protein derivatives of the hIFN-γ that preserve affinity to the hIFN-γ receptor are useful in the treatment of autoimmune diseases, especially multiple sclerosis.... Agent:

20110218326 - Plant-protein product and method for preparing the same: A plant-protein product and the method for preparing the same are provided. The plant-protein product is obtained from a plant-protein raw material which is treated by a single-cell separation technique, and the method for preparing the plant-protein product comprises steps of providing the plant-protein raw material; and treating the plant-protein... Agent: Zen-u Biotechnology Co., Ltd.

20110218327 - Method for providing a β-lactoglobulin product and an a-enriched whey protein isolate: The present invention relates to isolation of whey proteins and the preparation of a whey product and a whey isolate. In particular the present invention relates to the isolation of a β-lactoglobulin product and the isolation of an α-enriched whey protein isolate from whey obtained from an animal. The α-enriched... Agent: Upfront Chromatography A/s

20110218329 - Anti-il-6 antibodies, compositions, methods and uses: The present invention relates to at least one novel chimeric, humanized or CDR-grafted anti-IL-6 antibodies derived from the murine CLB-8 antibody, including isolated nucleic acids that encode at least one such anti-IL-6 antibody, vectors, host cells, transgenic animals or plants, and methods of making and using thereof, including therapeutic compositions,... Agent:

20110218328 - Treatment and prophylaxis of amyloidosis: Methods useful for effecting prophylaxis or treatment of amyloidosis, including AA Amyloidosis and AL amyloidosis, by administering peptides comprising neoepitopes, such as AA fragments from a C-terminal region of AA, and antibodies specific for neoepitopes of aggregated amyloid proteins, for example, antibodies specific for the C-terminal region of AA fibrils.... Agent: University Of Tennessee Research Foundation

20110213120 - Rosin esters for non-woven applications, methods of making and using and products therefrom: Rosin esters having suitable color, color stability and/or odor to make them useful for non-woven applications, to non-woven products made from and/or comprising rosin esters, and to methods of making and using such rosin esters and products.... Agent: Arizona Chemical Company

20110213121 - Nanoparticle sensor for measuring protease activity and method for manufacturing the same: Disclosed are a nanoparticle sensor for measuring protease activity, for protease imaging, and a method for preparing the same. More specifically, the present invention relates to a nanoparticle sensor for measuring protease activity in which a fluorophore- and a quencher-conjugated peptide substrate is conjugated to a biocompatible polymer nanoparticle. The... Agent:

20110213122 - Obtaining cocoa extracts rich in bioactive peptides with ace and pep enzyme inhibitory activity: The present invention relates to obtaining bioactive peptides from plant raw materials, specifically cocoa extracts, by means of enzyme treatment. Said biopeptides have angiotensin converting enzyme (ACE) and prolyl endopeptidase enzyme (PEP) inhibitory activity in vitro and/or antioxidant activity in vivo, being able to be used in the food, dietetic... Agent: Biopolis, S.l.

20110213123 - Compositions and methods for modification of biomolecules: The present invention provides modified cycloalkyne compounds; and method of use of such compounds in modifying biomolecules. The present invention features a cycloaddition reaction that can be carried out under physiological conditions. In general, the invention involves reacting a modified cycloalkyne with an azide moiety on a target biomolecule, generating... Agent:

20110213124 - Methods and systems for synthesis of a d-aminoluciferin precursor and related compounds: Methods and systems to generate 6-amino-6-deoxy-D-luciferin precursor, 2-cyano-6-aminobenzothiazole and related compounds and derivatives... Agent:

20110213125 - Humanized antibodies against human interferon-alpha: The present invention provides humanized anti-human IFN-α monoclonal antibodies useful for therapeutic applications in humans. Preferred antibodies are humanized versions of murine antibodies ACO-1 and ACO-2, as well as variants thereof.... Agent: Novo Nordisk A/s

20110213126 - Two-stage ultrafiltration/diafiltration: The present invention provides a method for concentrating a protein, in particular a method for concentrating a plasma product, in particular IgG, using glycine in a (two-stage ultrafiltration/diafiltration approach.... Agent: Talecris Biotherapeutics, Inc.

20110213127 - Methods for using and identifying modulators of delta-like 4: In certain embodiments, this present invention provides antibodies that act as either agonists or antagonists of Delta-like 4 (Dll4) signaling.... Agent: Vasgene Therapeutics, Inc.

20110213128 - Sirna capable of inhibiting the expression of an oncogene involved in cervical cancer: The present invention identifies the total nucleotide sequence of a novel oncogene from human, which is directly involved in such a cancerization mechanism as for cervical cancer induced by HPV infection of cervical epithelial cell and the amino acid sequence of an oncogenic protein encoded thereby, and to provide a... Agent: Masahiko Kuroda

20110213129 - Diagnostics and treatments of periodontal disease: This invention relates to the PrtR-PrtK cell surface protein of Porphyromonas gingivalis and in particular a multimeric cell association protein complex comprising the PrtR and PrtK proteins. Accordingly the invention provides a substantially purified antigenic complex for use in raising an antibody response directed against Porphyromonas gingivalis. The complex comprises... Agent: The University Of Melbourne

20110213130 - Novel inhibitors of vascular endothelial growth factor activity, their uses and processes for their production: The present invention is directed to novel chimeric VEGF receptor proteins comprising amino acid sequences derived from the vascular endothelial growth factor (VEGF) receptors flt-1 and KDR, including the murine homologue to the human KDR receptor FLK-1, wherein said chimeric VEGF receptor proteins bind to VEGF and antagonize the endothelial... Agent: Genentech, Inc.

20110213131 - Method of acylating a peptide or protein: A method has for selectively acylating an amino group in a peptide or protein which has two or more reactive nucleophilic functional groups is described.... Agent: Novo Nordisk A/s

20110213132 - Production of ngf in plant: The invention relates to genetically modified plants capable of producing a human recombinant protein Nerve Growth Factor, either in the form of pre-pro-protein or in the mature form and parts and differentiated and undifferentiated tissues thereof. The invention relates, also, to methods for the transformation of said plants in a... Agent:

20110213133 - Device for and method of extracting a fraction from a biological sample: A device and method are provided for facilitating extraction of a fraction from a biological sample. The biological sample includes non-desired material and a fraction-bound solid phase substrate. The device includes an input zone for receiving the biological sample therein and a phase-gate zone for receiving an isolation buffer therein.... Agent: